Barclays analyst Balaji Prasad lowered the firm’s price target on Ligand Pharmaceuticals to $110 from $120 and keeps an Overweight rating on the shares ahead of the Q2 results.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on LGND: